Taken together, both human and canine DLBCL express XPO1 and SINE compounds show potent activity against these tumor cells, suggesting a potential therapeutic benefit for human and canine patients with DLBCL. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.